You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 27, 2026

Drugs Containing Excipient (Inactive Ingredient) ANHYDROUS CITRIC ACID


✉ Email this page to a colleague

« Back to Dashboard


Branded drugs containing ANHYDROUS CITRIC ACID excipient, and estimated key patent expiration / generic entry dates

ANHYDROUS CITRIC ACID Market Analysis and Financial Projection

Last updated: February 14, 2026

What Are the Market Drivers for Anhydrous Citric Acid?

Anhydrous citric acid is a widely used pharmaceutical excipient, valued for its buffering capacity, pH regulation, and stabilizing properties. Its global market is influenced primarily by the growth of pharmaceutical manufacturing, demand for nutraceutical formulations, and regulatory compliance for excipients.

The drug industry expansion, especially in developing regions, increases the requirement for excipients, including anhydrous citric acid, particularly in formulations involving enzymatic activity, acids, and electrolytes.

How Does the Market for Anhydrous Citric Acid Evolve Globally?

The global market size for citric acid, including anhydrous forms, was valued at approximately USD 1.5 billion in 2021 and is projected to reach USD 2.0 billion by 2028, growing at a CAGR of around 4.8% during 2022–2028 [1].

Key regional markets:

  • Asia-Pacific: Leads in growth, driven by China and India’s pharmaceutical manufacturing and food processing industries. Growth rate exceeds global average, about 6% CAGR.
  • North America: Accounts for over 30% of demand, driven by regulations governing pharmaceutical excipients and a large generic drug segment.
  • Europe: Stabilizes, with high purity requirements and stringent regulations for excipients.

What Are the Core Market Segments?

Pharmaceutical Applications

Anhydrous citric acid is used in tablet coatings, effervescent formulations, and as a stabilizer in injectable drugs. Its role in maintaining pH stability makes it critical for biologics and sterile formulations.

Food and Beverage Industry

The majority of citric acid is used in food products, but pharmaceutical-grade anhydrous citric acid caters to health supplements and medicinal syrups, requiring high purity standards.

Nutraceuticals

Demand increases with the rise in demand for dietary supplements, where it acts as a chelating agent and acidulant.

Others

Cosmetics and personal care products utilize citric acid for pH adjustment.

What Are Factors Affecting Supply and Pricing?

Raw Material Availability

Manufacture depends on the availability of natural or synthetic citric acid production feedstocks, primarily sugar-derived glucose. Fluctuating sugar prices influence production costs.

Regulatory Standards

U.S. FDA, EMA, and other agencies enforce strict standards for pharmaceutical-grade citric acid, affecting manufacturing processes and costs.

Production Capacity & Consolidation

Major producers include Cargill, Archer Daniels Midland, and Jungbunzlauer. Market consolidation could lead to pricing power but also to supply chain vulnerabilities.

Quality & Purity Standards

High-purity anhydrous citric acid (USP, EP, BP grade) commands premium prices. Demand for pharmaceutical-grade material is rising, increasing competition for quality suppliers.

Supply Chain Disruptions

COVID-19 pandemic revealed vulnerabilities in logistics and raw material supply, impacting lead times and prices.

What Is the Financial Trajectory for Anhydrous Citric Acid?

Revenue Growth

The pharmaceutical excipient sector maintains steady growth with high-margin opportunities. Industry reports forecast compounded annual growth rates (CAGR) of 4–6% over the next five years for premium-quality anhydrous citric acid. Companies investing in capacity expansions and R&D could realize higher margins.

Price Trends

Prices have experienced modest inflation, approximately 2–3% annually, driven by raw material costs and regulatory compliance expenses. Short-term volatility remains due to raw material price swings and supply chain disruptions.

Investment Opportunities

  • Manufacturing capacity expansion to meet rising demand globally.
  • R&D investments aimed at developing microcrystalline or specially purified grades tailored for biopharmaceuticals.
  • Vertical integration in raw material supply chains to mitigate raw material cost volatility.

Risks

  • Regulatory changes increasing compliance costs.
  • Raw material shortages due to climate change or geopolitical tensions.
  • Competitive pressure from synthetic or natural sources.

How Do Regulations Impact Market Growth?

Regulatory frameworks prioritize purity, consistency, and safety. Pharmacopoeias (USP, EP, BP) specify limits and test methods. Increasing mandates for good manufacturing practices (GMP) elevate operational costs. Non-compliance limits access to certain markets or results in product recalls, impacting financial stability.

What Are the Competitive Dynamics?

Major Players

  • Jungbunzlauer
  • Cargill
  • Archer Daniels Midland
  • Tate & Lyle

Market Strategies

Integrating vertically to control raw material supply, investing in R&D for specialized grades, and expanding regional manufacturing facilities define dominant strategies.

Patent and IP Landscape

While anhydrous citric acid is a commodity with limited patent barriers, proprietary manufacturing processes for purer grades or novel formulations constitute competitive advantages.

What Is the Outlook for Future Market Trajectory?

The global demand for pharmaceutical-grade anhydrous citric acid is projected to increase in line with the broader excipient market. Focus on high-purity, stable, and regulatory-compliant products will continue. Raw material costs and regulatory costs are central to pricing strategies. Regional growth in Asia-Pacific, alongside steady expansion in mature markets, supports revenue growth estimates.

Key Takeaways

  • Global market size for citric acid, including anhydrous forms, is expected to reach USD 2 billion by 2028.
  • The pharmaceutical segment dominates demand, especially in formulations requiring pH control and stabilization.
  • Regional growth is fastest in Asia-Pacific; North America and Europe maintain mature, regulated markets.
  • Raw material costs and regulatory compliance significantly influence supply and pricing.
  • Industry consolidation among large producers sustains pricing power but introduces supply chain risks.
  • Innovation toward specialized, high-purity forms offers potential for premium pricing and profit margins.

FAQs

1. What are the primary raw materials used in manufacturing anhydrous citric acid?
Sugar-derived glucose is the main raw material, with production primarily through fermentation processes using mold strains like Aspergillus niger.

2. How do regulatory standards differ across regions?
USP, EP, and BP specify minimum purity levels, tests for contaminants, and packaging standards. North American and European markets enforce stricter compliance, affecting manufacturing costs.

3. What is the typical price range for pharmaceutical-grade anhydrous citric acid?
Prices vary based on purity, grade, and volume but generally range from USD 2.5 to USD 4.0 per kilogram in bulk quantities.

4. How are supply chain disruptions impacting the market?
Disruptions lead to short-term shortages and price increases, especially for high-purity, pharmaceutical-grade materials. The trend emphasizes the need for supply chain resilience and diversification.

5. What emerging trends could influence future demand?
Growing demand for biopharmaceuticals, advanced nutraceuticals, and personalized medicine drive the need for high-quality excipients like anhydrous citric acid. Innovations in manufacturing processes may further shape market dynamics.


[1] Transparency Market Research, "Citric Acid Market by Form (Anhydrous and Monohydrate), Application (Food & Beverage, Pharmaceuticals, Personal Care), Region," 2022.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.